Bartłomiej Grala
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Bartłomiej Grala has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Cezary Szczylik
Department of Oncology, Military Institute of Medicine, 04-141 Warsaw, Poland
2 shared publications - Lubomir Bodnar
Faculty of Medical and Health Sciences, Siedlce University of Natural Sciences and Humanities, 08-110 Siedlce, Poland
2 shared publications - Rafał Stec
Department of Oncology, Medical University of Warsaw, 02-091 Warsaw, Poland
2 shared publications - Agnieszka Góralska
Department of Dermatology, Military Institute of Medicine, Szaserów 128 Street, 04-141 Warsaw, Poland
1 shared publication - Ewa Ziajka
Department of Dermatology, Military Institute of Medicine, Szaserów 128 Street, 04-141 Warsaw, Poland
1 shared publication - Krystyna Zieniuk
Pathology Department, Military Institute of Health Services in Warsaw, Szaserów Street 128, Warszawa, 04-141, Poland
1 shared publication
Latest Publications
- Open Access
- 25 June 2014
- Published by Springer Nature in Journal of Medical Case Reports
- Vol. 8 (1) , 226
Recurrent pyoderma gangrenosum precipitated by breast cancer: a case report and review of the literature
Pyoderma gangrenosum is a rare clinical entity of poorly understood pathogenesis, characterized by rapidly progressing skin necrosis. In around half of patients pyoderma gangrenosum is a manifestation of underlying systemic diseases, such as rheumatoid arthritis, inflammatory bowel disease or myeloproliferative disorders. There have been very few reports on the association of pyoderma gangrenosum with solid malignancies.
- 25 June 2014
- Published by Springer Nature in Journal of Medical Case Reports
- Vol. 8 (1) , 226
Open AccessRecurrent pyoderma gangrenosum precipitated by breast cancer: a case report and review of the literature
Pyoderma gangrenosum is a rare clinical entity of poorly understood pathogenesis, characterized by rapidly progressing skin necrosis. In around half of patients pyoderma gangrenosum is a manifestation of underlying systemic diseases, such as rheumatoid arthritis, inflammatory bowel disease or myeloproliferative disorders. There have been very few reports on the association of pyoderma gangrenosum with solid malignancies.
- Open Access
- 30 April 2013
- Published by Springer Nature in Journal of Experimental & Clinical Cancer Research
- Vol. 32 (1) , 25
Tau protein as a potential predictive marker in epithelial ovarian cancer patients treated with paclitaxel/platinum first-line chemotherapy
The aim of the study was to evaluate predictive and prognostic significance of microtubule-associated protein Tau in epithelial ovarian cancer (EOC) patients treated with paclitaxel and platinum-based chemotherapy.
- 30 April 2013
- Published by Springer Nature in Journal of Experimental & Clinical Cancer Research
- Vol. 32 (1) , 25
Open AccessTau protein as a potential predictive marker in epithelial ovarian cancer patients treated with paclitaxel/platinum first-line chemotherapy
The aim of the study was to evaluate predictive and prognostic significance of microtubule-associated protein Tau in epithelial ovarian cancer (EOC) patients treated with paclitaxel and platinum-based chemotherapy.
- Open Access
- 7 October 2009
- Published by Springer Nature in Journal of Experimental & Clinical Cancer Research
- Vol. 28 (1) , 134
Chromophobe renal cell cancer - review of the literature and potential methods of treating metastatic disease
Chromophobe renal cell carcinoma (ChRCC) is a subtype of renal cell carcinoma (RCC). ChRCC is diagnosed mainly in 6th decade of life. An incidence of ChRCC is similar in both men and woman. Eighty six percent of ChRCCs cases are diagnosed in stage 1 or 2. Prognosis of ChRCC is better than in other types of RCC. Five- and 10-year disease free survival (DFS) for ChRCC was 83.9% and 77.9%, respectively. Expression of immunohistological markers: cytokeratins (CK), vimentin, epithelial membrane antigen (EMA), CD10 could be potentially helpful in diagnosis of different subtypes of RCC. From all conventional RCC, CD 117 was detected (overexpression) in membrane of cells ChRCC.
- 7 October 2009
- Published by Springer Nature in Journal of Experimental & Clinical Cancer Research
- Vol. 28 (1) , 134
Open AccessChromophobe renal cell cancer - review of the literature and potential methods of treating metastatic disease
Chromophobe renal cell carcinoma (ChRCC) is a subtype of renal cell carcinoma (RCC). ChRCC is diagnosed mainly in 6th decade of life. An incidence of ChRCC is similar in both men and woman. Eighty six percent of ChRCCs cases are diagnosed in stage 1 or 2. Prognosis of ChRCC is better than in other types of RCC. Five- and 10-year disease free survival (DFS) for ChRCC was 83.9% and 77.9%, respectively. Expression of immunohistological markers: cytokeratins (CK), vimentin, epithelial membrane antigen (EMA), CD10 could be potentially helpful in diagnosis of different subtypes of RCC. From all conventional RCC, CD 117 was detected (overexpression) in membrane of cells ChRCC.